Share

|

|

|

Analysis points to FOLFIRINOX chemotherapy benefits for metastatic pancreatic cancer

FOLFIRINOX chemotherapy may offer better survival than gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma, suggests a comparative effectiveness study published in JAMA Network Open.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Adolescent, young adult patients might benefit from intensive rhabdomyosarcoma treatment

Adolescent and young adults with rhabdomyosarcoma have more aggressive disease than their paediatric counterparts and might benefit from intensive treatment strategies, suggests an analysis of two European paediatric Soft tissue sarcoma Study Group trials.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

ICIs associated with increased MACE risk

People with cancer receiving immune checkpoint inhibitors have a significantly higher risk for major adverse cardiovascular events than their unexposed counterparts or the general population, indicate real-world findings.